Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
novartis
30 tablet
Pazopanib
Keep in cold place
Delivering To:
Overview
Soft tissue sarcoma (a tumor that develops in the muscles, joints, organs, tendons, or blood vessels) and kidney cancer (renal cell carcinoma) are treated with Votrient 400mg tablets. Pazopanib 400mg is found in Votrient Tablets, which are administered after other therapies have failed. Pazopanib is a member of the class of tyrosine kinase inhibitors.
kidney cancer
Kidney cancer
Soft tissue sarcoma
Votrient 400mg tablet has several side effects, which are:
Dizziness
Problem in speaking
Headache
Breathing problem
Pain in the arm or leg
Chest pain
Irregular heartbeat
Cough
Nose bleeds
Bloody urine
Vomiting
Stomach pain
Delay in wound healing
Weight loss
If the above-mentioned symptoms are seen in the patients and are not tolerable, immediately consult the doctor.
Votrient 400mg tablet is a very powerful drug; taking it in the wrong way may give severe side effects and increase the duration of treatment. You have to follow the doctor's prescription strictly for better results. In case of overdose, immediately consult a doctor for medical attention. Swallow it as a whole. Do not chew, crush, or break it. Votrient 400mg Tablet is to be taken on an empty stomach.
One anti-cancer drug is Votrient 400mg Tablet. Tyrosine kinase enzyme receptors, which are in charge of the growth of malignant cells, are bound and inhibited by it. Additionally, it prevents new blood vessels from growing inside the tumor. It reduces cancer in this way.
Alcohol
unsafe
It is advisable not to consume alcohol while taking this medicine.
Pregnancy
consult your doctor
Do not take the Votrient 400mg tablet without consulting the doctor in case of pregnancy. There is clear evidence that using Votrient 400mg Tablets during pregnancy causes a risk to the growing baby.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding.Using Votrient 400mg Tablets during breastfeeding is not advised. Evidence suggests to the drug's potential to be hazardous to the unborn child.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
caution
Do not take the Votrient 400mg tablet without a doctor's consultation in case of kidney problems.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine.Patients with liver illness should use the 400 mg Votrient tablet with caution. Votrient 400mg Tablet dosage may need to be changed. Please speak with your physician. Patients with moderate to severe liver illness should not take Votrient 400mg tablets.
In case you missed any dose consult your doctor. Do not take twice the dose to catch up on the missed dose. This will cause severe side effects and impact your overall health.
Votrient 400mg tablet is used to treat kidney cancer.
The duration of treatment will depend on the stage of cancer and the overall health of the patients.
Driving and operating heavy machinery is not advisable because this tablet makes you feel dizzy.
Consult your doctor immediately in such cases, as these medicines can harm the unborn baby. Do not take it before consulting the doctor.
400 mg votrient tablet should be taken orally, once a day, or as directed by your physician. Because breaking or crushing a tablet may change how the medication is absorbed and possibly increase adverse effects, it is vital to swallow the tablet whole with water.
A common adverse effect of Votrient 400mg tablet medication is a change in hair color, which often appears gradually over the course of a few months of treatment. For additional guidance, speak with your physician.
Votrient 400mg Tablet therapies vary from person to person. To assess the treatment's efficacy and establish how long you should take it, your doctor will perform routine examinations.
Kwon, J. H., Lee, S. E., Choi, J. Y., Kim, H. Y., & Park, S. H. (2024). Real-world outcomes of pazopanib in advanced soft tissue sarcoma: A multicenter study in Korea. Cancer Medicine, 13(5), 2173–2182.
Ravaud, A., Motzer, R. J., & Sternberg, C. N. (2023). Long-term safety of pazopanib in advanced renal cell carcinoma: A pooled analysis of clinical trial data. Clinical Genitourinary Cancer, 21(2), e137–e145.
Singh, A., Mehra, N., & Kapoor, A. (2023). Comparative safety and efficacy of pazopanib versus sunitinib in metastatic renal cell carcinoma: A meta-analysis. Journal of Oncology Pharmacy Practice, 29(4), 301–309.
Tan, A. R., Weiss, G. J., Bilen, M. A., Sonpavde, G., & George, S. (2023). Pharmacokinetics and exposure–response relationship of pazopanib in patients with renal cell carcinoma and sarcoma. Clinical Pharmacokinetics, 62(3), 347–358.
Van Der Graaf, W. T., Gelderblom, H., & Mathijssen, R. H. J. (2024). Does individualization of pazopanib in soft tissue sarcoma: The case for therapeutic drug monitoring? European Journal of Cancer, 190, 1–9.
Verheijen, R. B., Lolkema, M. P. J., de Bruijn, P., et al. (2024). Optimizing pazopanib dosing: Evaluation of reduced-dose strategies in oncology patients. British Journal of Clinical Pharmacology, 90(2), 389–400.
